Phase II Trial of Irinotecan for Treatment of Metastatic Medullary Thyroid Cancer
- Determine the response rate in patients with metastatic or inoperable locoregional
medullary thyroid cancer treated with irinotecan.
- Determine the safety and tolerability of this drug in these patients.
OUTLINE: Patients receive irinotecan IV on days 1 and 8. Treatment repeats every 21 days for
4 courses in the absence of disease progression or unacceptable toxicity. Response is
assessed after completion of 4 courses. Patients achieving complete response (CR) or partial
response (PR) receive 2 additional courses beyond CR or PR. Patients who have stable disease
receive up to 12 total courses.
PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Arlene A. Forastiere, MD
Sidney Kimmel Comprehensive Cancer Center
United States: Federal Government
|University of Michigan Comprehensive Cancer Center||Ann Arbor, Michigan 48109-0752|
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||Baltimore, Maryland 21231-2410|